Combination drug treatment for severe aplastic anemia
Part of Blood & lymphatic clinical trials.
This trial tests whether a new combination of medicines can help treat severe aplastic anemia (SAA) or a related type (TD-NSAA). It uses a drug that helps your body make more platelets, along with immunosuppressants, and may offer an alternative if a bone marrow transplant isn't possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of severe aplastic anemia (SAA) or a type of aplastic anemia that needs treatment (TD-NSAA).
- You must not have already been treated with immunosuppressants (like cyclosporine, tacrolimus, or ATG) for this condition.
- You either don't have a matched sibling for a bone marrow transplant, or a transplant isn't possible for you.
- Your liver and kidney function need to be within safe limits for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an experimental medicine called Dibotatug (DR-01) for adults with aplastic anemia, a condition where the bone marrow stops making enough blood cells. It aims to see if the drug is safe and can help improve blood cell counts, especially for people whose disease has not improved with standard treatments.
This trial tests a combination of drugs to help your bone marrow make more blood cells if you have aplastic anemia and cannot have a stem cell transplant or standard immune therapy. It might improve blood counts and reduce the need for transfusions.
This study looks at how well a standard combination of two medicines, cyclosporine and eltrombopag, works for people newly diagnosed with aplastic anemia (a condition where the bone marrow doesn't make enough blood cells). It aims to see if this treatment helps improve blood counts and overall outcomes.
This trial tests whether adding romiplostim, a drug that helps the body make platelets, to the usual treatment for severe aplastic anemia can improve blood cell counts. It is for people who have not yet started treatment for this condition.
This trial studies using a donor's blood stem cells (from bone marrow or blood) for a transplant in people with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if using a mix of both types of cells is better than just blood cells alone.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
Hear when a new Aplastic Anemias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.